Appropriate advancement of type 2 diabetes therapy
Recent guidelines recommend rapid advancement of antiglycemic therapy, with early initiation of insulin as a practical and effective option, but they offer little guidance for primary care physicians with respect to the practical implementation and inclusion of either basal or rapid-acting analogs into treatment regimens.These guidelines also do not adequately address the therapeutic role of some newer agents (eg, the incretin group). An editorial workgroup meeting consisting of a multidisciplinary panel of diabetes thought leaders recently convened to provide additional insight on these issues. Their recommendations and viewpoints are reported in this supplement (Current Clinical Practice)
Generex Announces Enrollment of Initial Subjects in Metformin Gum Trial
The protocol for the study is an open-label, two-treatment, two-period, randomized, crossover study comparing MetControl™ and immediate release Metformin tablets in healthy volunteers (Generex Biotechnology Corporation, USA)
Joslin receives $3 Million to study obesity
Joslin Diabetes Center has received a three-year, $3 million grant from the Eli Lilly and Company Foundation to help fund studies that will investigate the underlying causes of obesity and insulin resistance (Renal Business Today)
Beta-cell function improved with R-1583, a novel long-acting GLP-1 analogue
Researchers at Roche have reported phase II results from an 8-week, double-blind, placebo-controlled study evaluating taspoglutide (R-1583), a glucagon-like peptide-1 (GLP-1) receptor agonist, in type 2 diabetes patients inadequately controlled with metformin (American Diabetes Association)
Glutamic acid decarboxylase may help to preserve residual insulin secretion
Treatment with alum-formulated glutamic acid decarboxylase contributed to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, but did not change the insulin requirement in a recent study (Endocrine Today)
Novo Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm
Aradigm Corporation, a specialty pharmaceutical company, announced that Novo Nordisk transferred to Aradigm, at no charge, a portfolio of inhaled insulin related patents pursuant to a license agreement between Aradigm and Novo that was terminated in May 2008 (PharmaLive)
Putting the NICE Guideline on Type 2 Diabetes into Practice
In this article, we will focus on the important areas of patient education, dietary assessment, setting targets for HbA1c, self-monitoring and starting insulin therapy. 4-page PDF (British Journal of Primary Care Nursing)
Why do People with Diabetes Fall Off the Rails?
This article reviews what I found and offers some suggestions on how to help patients get back in control. 3-page PDF (British Journal of Primary Care Nursing)
Tackling Type 2 diabetes prevention
Diabetes UK held its first Frontiers in Diabetes meeting this week. The event looked at generating practical strategies for the prevention of Type 2 diabetes in the UK (Diabetes UK)
GPs in Scotland have wider type-2 diabetes treatment choice
GPs in Scotland now have a wider choice of treatments for type-2 diabetes following acceptance of the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin by the Scottish Medicines Consortium (Healthcare Republic)
Obesity Upregulates Genes Involved in Oxidative Phosphorylation in Livers of Diabetic Patients
Obesity may affect the pathophysiology of type 2 diabetes by upregulating genes involved in OXPHOS in association with insulin resistance markers and the expression of genes involved in hepatic gluconeogenesis and ROS generation (Obesity)
Clinical resolution of glycogenic hepatopathy following improved glycemic control
Glycogenic hepatopathy is an underrecognized complication of long-standing poorly controlled diabetes mellitus … It is important to distinguish this entity as it has the potential for resolution following improved glycemic control as described by this case report (Journal of Diabetes and its Complications)
Telmisartan may be potential treatment for high-risk diabetes, vascular disease
Patients with vascular disease or high-risk diabetes who are unable to tolerate ACE inhibitors may have reduced cardiovascular death, myocardial infarction or stroke with telmisartan treatment (Endocrine today)
The Incidence of Tinea Pedis in Diabetic versus Nondiabetic Patients with Interdigital Macerations
The prevalence in the nondiabetic group was 37.5% and 42.5% for the diabetic group. This was not a statistically significant difference (Journal of the American Podiatric Medical Association)
Live interactive webcast: Insulin pump therapy
Watch and participate in interviews and discussions with healthcare professionals, hear pumpers share their experiences and get views from support groups and one of the UK’s leading diabetes charities. 13th November 2008, 7.30pm – 8.30pm (diabetesLive)
DIAMAP
The mission of DIAMAP is to undertake a wide survey of the current European diabetes research landscape from which expert opinion can identify gaps and highlight strengths, to guide a Road Map strategy for diabetes in Europe (DIAMAP)
PPD contracted for juvenile diabetes research
US-based contract research organisation PPD has been selected as a full-service preferred provider for translational clinical development services by the Juvenile Diabetes Research Foundation (PharmaTimes)
Weight gain in early life predicts risk of islet autoimmunity in children with a first degree relative with type 1 diabetes
In a prospective birth cohort study we followed infants, who had a first-degree relative with type 1 diabetes, to investigate the relationship between early growth and infant feeding, and the risk of islet autoimmunity (Diabetes Care)
Impaired Vision Twice As Common in Diabetics
Vision loss is nearly twice as common among U.S. adults with diabetes as those without diabetes, according to research published today (American Diabetes Association)
International Diabetes Federation calls for global action to keep all children with diabetes alive
The International Diabetes Federation announced today that it is bringing together key opinion leaders to push for action to secure care for the thousands of children with diabetes in developing countries without access (IDF)
Levels Of Key Hormone During First Trimester Of Pregnancy Could Lead To Earlier Diagnosis Of Gestational Diabetes
New research shows women who develop diabetes during pregnancy (gestational diabetes mellitus) have reduced levels of an insulin-sensitive hormone, adiponectin, as early as nine weeks into the pregnancy (National Diabetes Support Team)
Diabetes screening brings huge cut in CVD risk
Screening for diabetes and treating newly identified cases can have a dramatic effect at reducing cardiovascular risk, new research concludes (PULSE)
FDA review of Takeda’s alogliptin will not be finished on time
Takeda Pharmaceutical Co is going to have to wait a bit longer to market alogliptin after US regulators said they need more time to evaluate the Japanese drugmaker’s experimental type 2 diabetes drug (PharmaTimes)
Sector Snap: Diabetes drug developers gain ground
A regulatory delay for Takeda Pharmaceuticals developing diabetes drug alogliptin helped boost shares of competitor Merck & Co. Monday, highlighting the competitive nature of diabetes drug development within the pharmaceutical and biotech sectors (Business Week)
Low Testosterone a Problem in Young Diabetic Men
About one third of young adult men with type 2 diabetes have low testosterone levels, research shows. (American Diabetes Association)
High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children
Epidemiological studies suggest a link between vitamin D deficiency in early life and the later onset of type 1 diabetes. (PubMed)
Parkinson’s disease was not a risk factor for diabetes
The prevalence of diabetes was similar — albeit slightly lower — among patients with Parkinson’s disease compared with patients without the disease, (Endocrine Today)
Glycosmedia is also available as an App: